Provided that SGLT2‐Is exhibit beneficial effects through the modulation of the CNS microenvironment, these inhibitors may contribute to reducing the risk of AD developing in T2DM patients, in addition to their therapeutic use as dual inhibitors of SGLT2 and AChE.9, 10 The influences of SGLT2‐Is use on brain functions and AD progression deserve further investigations for the better care and safety of DM patients. This evidence concerns the gene SLC5A2 and diabetes mellitus.